Last reviewed · How we verify
BioCart™II
BioCart™II is a Viscosupplement Biologic drug developed by ProChon Biotech Ltd. It is currently in Phase 2 development for Treatment of osteoarthritis of the knee. Also known as: Autologous chondrocyte implantation, ACI.
BioCart II is a hyaluronic acid-based viscosupplement used to treat joint pain and inflammation.
BioCart II is a hyaluronic acid-based viscosupplement used to treat joint pain and inflammation. Used for Treatment of osteoarthritis of the knee.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | BioCart™II |
|---|---|
| Also known as | Autologous chondrocyte implantation, ACI |
| Sponsor | ProChon Biotech Ltd |
| Drug class | Viscosupplement |
| Modality | Biologic |
| Therapeutic area | Rheumatology |
| Phase | Phase 2 |
Mechanism of action
BioCart II works by injecting a gel-like substance into the affected joint to provide cushioning and lubrication, reducing friction and pain. This is particularly useful for treating osteoarthritis and other degenerative joint conditions.
Approved indications
- Treatment of osteoarthritis of the knee
Common side effects
- Pain, swelling, or redness at the injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BioCart™II CI brief — competitive landscape report
- BioCart™II updates RSS · CI watch RSS
- ProChon Biotech Ltd portfolio CI
Frequently asked questions about BioCart™II
What is BioCart™II?
How does BioCart™II work?
What is BioCart™II used for?
Who makes BioCart™II?
Is BioCart™II also known as anything else?
What drug class is BioCart™II in?
What development phase is BioCart™II in?
What are the side effects of BioCart™II?
Related
- Drug class: All Viscosupplement drugs
- Manufacturer: ProChon Biotech Ltd — full pipeline
- Therapeutic area: All drugs in Rheumatology
- Indication: Drugs for Treatment of osteoarthritis of the knee
- Also known as: Autologous chondrocyte implantation, ACI
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing